{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:39:04Z","timestamp":1794411544319,"version":"4.9.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T00:00:00Z","timestamp":1510617600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s40265-017-0835-9","type":"journal-article","created":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T03:51:32Z","timestamp":1510631492000},"page":"1987-2001","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":270,"title":["Tofacitinib: A Review in Rheumatoid Arthritis"],"prefix":"10.1007","volume":"77","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,14]]},"reference":[{"issue":"3","key":"835_CR1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrrheum.2013.7","volume":"9","author":"JJ O\u2019Shea","year":"2013","unstructured":"O\u2019Shea JJ, Laurence A, McInnes IB, et al. Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat Rev Rheumatol. 2013;9(3):173\u201382.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"835_CR2","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960\u201377.","journal-title":"Ann Rheum Dis"},{"issue":"4 Suppl 98","key":"835_CR3","first-page":"69","volume":"34","author":"KL Winthrop","year":"2016","unstructured":"Winthrop KL, Strand V, van der Heijde DM, et al. The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016. Clin Exp Rheumatol. 2016;34(4 Suppl 98):69\u201376.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"835_CR4","first-page":"318","volume":"34","author":"JA Hodge","year":"2016","unstructured":"Hodge JA, Kawabata TT, Krishnaswami S, et al. The mechanism of action of tofacitinib\u2014an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(2):318\u201328.","journal-title":"Clin Exp Rheumatol"},{"key":"835_CR5","unstructured":"Pfizer Ltd. Xeljanz (tofacitinib): summary of product characteristics. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004214\/WC500224911.pdf . Accessed 31 Oct 2017."},{"issue":"8","key":"835_CR6","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40265-013-0065-8","volume":"73","author":"LJ Scott","year":"2013","unstructured":"Scott LJ. Tofacitinib: a review of its use in adult patients with rheumatoid arthritis. Drugs. 2013;73(8):857\u201374.","journal-title":"Drugs."},{"key":"835_CR7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-9255-7-41","volume":"7","author":"DM Meyer","year":"2010","unstructured":"Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm. 2010;7:41.","journal-title":"J Inflamm"},{"issue":"1","key":"835_CR8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","volume":"26","author":"MW Karaman","year":"2008","unstructured":"Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26(1):127\u201332.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"835_CR9","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/art.34329","volume":"64","author":"K Maeshima","year":"2012","unstructured":"Maeshima K, Yamaoka K, Kubo S, et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-gamma and interleukin-17 production by human CD4\u00a0+\u00a0T cells. Arthritis Rheum. 2012;64(6):1790\u20138.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"835_CR10","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/annrheumdis-2014-206028","volume":"74","author":"DL Boyle","year":"2015","unstructured":"Boyle DL, Soma K, Hodge J, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis. 2015;74(6):1311\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"835_CR11","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1136\/annrheumdis-2015-208267","volume":"75","author":"PG Conaghan","year":"2016","unstructured":"Conaghan PG, Ostergaard M, Bowes MA, et al. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques. Ann Rheum Dis. 2016;75(6):1024\u201333.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"835_CR12","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1002\/art.34649","volume":"64","author":"TP LaBranche","year":"2012","unstructured":"LaBranche TP, Jesson MI, Radi ZA, et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum. 2012;64(11):3531\u201342.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"835_CR13","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1136\/annrheumdis-2016-eular.1413","volume":"75","author":"M Kitano","year":"2016","unstructured":"Kitano M, Kitano S, Sekiguchi M, et al. Early effect of tofacitinib on osteoclast regulator in rheumatoid arthritis [abstract no. AB0394]. Ann Rheum Dis. 2016;75(Suppl 2):1040.","journal-title":"Ann Rheum Dis"},{"key":"835_CR14","doi-asserted-by":"crossref","unstructured":"van Vollenhoven R, Choy E, Lee EB, et al. Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: changes in lymphocytes and lymphocyte subset counts and reversibility after up to 8\u00a0years of tofacitinib treatment [abstract no. THU0199]. Ann Rheum Dis. 2016;75(Suppl 2).","DOI":"10.1136\/annrheumdis-2016-eular.2134"},{"issue":"1","key":"835_CR15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2012-202442","volume":"73","author":"IB McInnes","year":"2014","unstructured":"McInnes IB, Kim HY, Lee SH, et al. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Ann Rheum Dis. 2014;73(1):124\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"835_CR16","doi-asserted-by":"crossref","first-page":"R158","DOI":"10.1186\/ar4673","volume":"16","author":"JD Isaacs","year":"2014","unstructured":"Isaacs JD, Zuckerman A, Krishnaswami S, et al. Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials. Arthritis Res Ther. 2014;16(4):R158.","journal-title":"Arthritis Res Ther."},{"issue":"4","key":"835_CR17","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","volume":"75","author":"KL Winthrop","year":"2016","unstructured":"Winthrop KL, Silverfield J, Racewicz A, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis. 2016;75(4):687\u201395.","journal-title":"Ann Rheum Dis"},{"issue":"25","key":"835_CR18","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377\u201386.","journal-title":"N Engl J Med"},{"issue":"6","key":"835_CR19","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495\u2013507.","journal-title":"N Engl J Med"},{"issue":"10093","key":"835_CR20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390(10093):457\u201368.","journal-title":"Lancet"},{"issue":"3","key":"835_CR21","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D Heijde van der","year":"2013","unstructured":"van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559\u201370.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"835_CR22","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF Vollenhoven van","year":"2012","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508\u201319.","journal-title":"N Engl J Med"},{"issue":"4","key":"835_CR23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","volume":"159","author":"J Kremer","year":"2013","unstructured":"Kremer J, Li ZG, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159(4):253\u201361.","journal-title":"Ann Intern Med"},{"issue":"9865","key":"835_CR24","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451\u201360.","journal-title":"Lancet"},{"issue":"1","key":"835_CR25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10067-016-3436-1","volume":"36","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mease PJ, Schwartzman S, et al. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group. Clin Rheumatol. 2017;36(1):15\u201324.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"835_CR26","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-016-1106-y","volume":"18","author":"RB Landewe","year":"2016","unstructured":"Landewe RB, Connell CA, Bradley JD, et al. Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials. Arthritis Res Ther. 2016;18(1):212.","journal-title":"Arthritis Res Ther."},{"issue":"6","key":"835_CR27","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/rheumatology\/kev442","volume":"55","author":"V Strand","year":"2016","unstructured":"Strand V, van Vollenhoven RF, Lee EB, et al. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis. Rheumatology (Oxford). 2016;55(6):1031\u201341.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"835_CR28","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/acr.23004","volume":"69","author":"V Strand","year":"2017","unstructured":"Strand V, Kremer JM, Gruben D, et al. Tofacitinib in combination with conventional disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: patient-reported outcomes from a phase III randomized controlled trial. Arthritis Care Res (Hoboken). 2017;69(4):592\u20138.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"4","key":"835_CR29","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/acr.22453","volume":"67","author":"V Strand","year":"2015","unstructured":"Strand V, Burmester GR, Zerbini CA, et al. Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial. Arthritis Care Res (Hoboken). 2015;67(4):475\u201383.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"835_CR30","doi-asserted-by":"crossref","unstructured":"Strand V, Mysler E, Moots RJ, et al. Tofacitinib with and without methotrexate versus adalimumab with methotrexate for the treatment of rheumatoid arthritis: patient-reported outcomes from a phase 3b\/4 randomized trial [abstract no. 1906]. Arthritis Rheumatol. 2017;69(Suppl 10).","DOI":"10.1136\/annrheumdis-2018-eular.1312"},{"key":"835_CR31","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s13075-015-0825-9","volume":"17","author":"V Strand","year":"2015","unstructured":"Strand V, Kremer J, Wallenstein G, et al. Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. Arthritis Res Ther. 2015;17:307.","journal-title":"Arthritis Res Ther."},{"issue":"2","key":"835_CR32","doi-asserted-by":"crossref","first-page":"e000308","DOI":"10.1136\/rmdopen-2016-000308","volume":"2","author":"V Strand","year":"2016","unstructured":"Strand V, Lee EB, Fleischmann R, et al. Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial. RMD Open. 2016;2(2):e000308.","journal-title":"RMD Open."},{"issue":"5","key":"835_CR33","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3899\/jrheum.130683","volume":"41","author":"J Wollenhaupt","year":"2014","unstructured":"Wollenhaupt J, Silverfield J, Lee EB, et al. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol. 2014;41(5):837\u201352.","journal-title":"J Rheumatol"},{"key":"835_CR34","doi-asserted-by":"crossref","unstructured":"Wollenhaupt J, Silverfield J, Lee EB. Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9\u00a0years [abstract no. 522]. Arthritis Rheumatol. 2017;69(Suppl 10).","DOI":"10.1136\/annrheumdis-2018-eular.1733"},{"key":"835_CR35","unstructured":"van der Heijde D, Wollenhaupt J, Cohen SB, et al. Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib: data from an open-label long-term extension study over 3\u00a0years [abstract no. 533]. 2017;69(Suppl 10)."},{"issue":"7","key":"835_CR36","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1136\/annrheumdis-2014-207178","volume":"75","author":"C Charles-Schoeman","year":"2016","unstructured":"Charles-Schoeman C, Burmester G, Nash P, et al. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2016;75(7):1293\u2013301.","journal-title":"Ann Rheum Dis"},{"key":"835_CR37","unstructured":"Hall S, Nash P, Rischmueller M, et al. Efficacy of tofacitinib in patients who are inadequate responders to disease-modifying antirheumatic drugs according to early versus late duration of rheumatoid arthritis: post-hoc analysis of data from phase 3 trials [abstract no. 1609]. Arthritis Rheumatol. 2016;68(Suppl 10)."},{"key":"835_CR38","unstructured":"Dikranian A, Gonzalez-Gay MA, Wellborne F, et al. The efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index [abstract no. 2371]. Arthritis Rheumatol. 2017;69(Suppl 10)."},{"key":"835_CR39","doi-asserted-by":"crossref","unstructured":"Tesser J, G\u00fcl A, Olech E, et al. Efficacy and safety of tofacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to prior therapies [abstract no. 2493]. Arthritis Rheumatol. 2017;69(Suppl 10).","DOI":"10.1136\/annrheumdis-2017-eular.1828"},{"key":"835_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-0932-2","author":"H Yamanaka","year":"2016","unstructured":"Yamanaka H, Tanaka Y, Takeuchi T, et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther. 2016. https:\/\/doi.org\/10.1186\/s13075-016-0932-2 .","journal-title":"Arthritis Res Ther."},{"key":"835_CR41","doi-asserted-by":"crossref","unstructured":"An Y, Li Z, Wu Q. Efficacy and safety of tofacitinib in chinese patients with active rheumatoid arthritis: subgroup analysis from a phase 3 study of tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs [abstract no. AB0514]. Ann Rheum Dis. 2015;74(Suppl 2).","DOI":"10.1136\/annrheumdis-2015-eular.4278"},{"issue":"4","key":"835_CR42","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.reuma.2016.04.010","volume":"13","author":"SC Radominski","year":"2017","unstructured":"Radominski SC, Cardiel MH, Citera G, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: pooled efficacy and safety analyses of phase 3 and long-term extension studies. Reumatol Clin. 2017;13(4):201\u20139.","journal-title":"Reumatol Clin."},{"issue":"1","key":"835_CR43","first-page":"32","volume":"34","author":"SB Cohen","year":"2016","unstructured":"Cohen SB, Koenig A, Wang L, et al. Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III. Clin Exp Rheumatol. 2016;34(1):32\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"835_CR44","first-page":"390","volume":"35","author":"JR Curtis","year":"2017","unstructured":"Curtis JR, Schulze-Koops H, Takiya L, et al. Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis. Clin Exp Rheumatol. 2017;35(3):390\u2013400.","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"835_CR45","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","volume":"76","author":"SB Cohen","year":"2017","unstructured":"Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5\u00a0years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76(7):1253\u201362.","journal-title":"Ann Rheum Dis"},{"key":"835_CR46","unstructured":"European Medicines Agency. Xeljanz (tofacitinib): assessment report. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/004214\/WC500224913.pdf . Accessed 31 Oct 2017."},{"key":"835_CR47","unstructured":"Pope J, Keystone E, Jamal S, et al. Persistence of tofacitinib in the treatment of rheumatoid arthritis in open-label, long-term extension studies up to 8\u00a0years [abstract no. 1602]. Arthritis Rheumatol. 2016;68(Suppl 10)."},{"issue":"Suppl 2","key":"835_CR48","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/annrheumdis-2016-eular.1332","volume":"75","author":"K Winthrop","year":"2016","unstructured":"Winthrop K, Wouters A, Choy E, et al. Assessment of immunogenicity of live zoster vaccination in rheumatoid arthritis patients on background methotrexate before and after initiating tofacitinib or placebo [abstract no. FRI0110]. Ann Rheum Dis. 2016;75(Suppl 2):468.","journal-title":"Ann Rheum Dis"},{"key":"835_CR49","unstructured":"Nurmohamed M, Choy E, Charles-Schoeman C, et al. Impact of tofacitinib treatment compared with placebo or methotrexate on cardiovascular risk scores in six phase 3 randomized controlled trials [abstract no. 2966]. Arthritis Rheumatol. 2017;69(Suppl 10)."},{"issue":"1","key":"835_CR50","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/rheumatology\/kew329","volume":"56","author":"H Schulze-Koops","year":"2017","unstructured":"Schulze-Koops H, Strand V, Nduaka C, et al. Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies. Rheumatology (Oxford). 2017;56(1):46\u201357.","journal-title":"Rheumatology (Oxford)"},{"key":"835_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23421","author":"X Mariette","year":"2017","unstructured":"Mariette X, Chen C, Biswas P, et al. Lymphoma in the tofacitinib rheumatoid arthritis clinical development program. Arthritis Care Res (Hoboken). 2017. https:\/\/doi.org\/10.1002\/acr.23421 .","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"12","key":"835_CR52","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1002\/acr.21764","volume":"64","author":"JR Curtis","year":"2012","unstructured":"Curtis JR, Lanas A, John A, et al. Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(12):1819\u201328.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"10086","key":"835_CR53","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","volume":"389","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;389(10086):2338\u201348.","journal-title":"Lancet"},{"key":"835_CR54","unstructured":"Eli Lilly Nederland B.V. Olumiant\u00ae (baricitinib): summary of product characteristics. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004085\/WC500223723.pdf . Accessed 31 Oct 2017."},{"key":"835_CR55","unstructured":"National Institute of Health and Care Excellence. Tofacitinib for moderate to severe rheumatoid arthritis: technology appraisal guidance. 2017. https:\/\/www.nice.org.uk\/guidance\/ta480 . Accessed 31 Oct 2017."},{"key":"835_CR56","unstructured":"National Institute of Health and Care Excellence. Baricitinib for moderate to severe rheumatoid arthritis. 2017. https:\/\/www.nice.org.uk\/guidance\/ta466 . Accessed 31 Oct 2017."},{"key":"835_CR57","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1741-7015-12-43","volume":"12","author":"A Mocsai","year":"2014","unstructured":"Mocsai A, Kovacs L, Gergely P. What is the future of targeted therapy in rheumatology: biologics or small molecules? BMC Med. 2014;12:43.","journal-title":"BMC Med."},{"issue":"4","key":"835_CR58","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","volume":"13","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234\u201343.","journal-title":"Nat Rev Rheumatol"},{"key":"835_CR59","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s13075-015-0880-2","volume":"17","author":"V Strand","year":"2015","unstructured":"Strand V, Ahadieh S, French J, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther. 2015;17:362.","journal-title":"Arthritis Res Ther."},{"issue":"10","key":"835_CR60","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","volume":"66","author":"KL Winthrop","year":"2014","unstructured":"Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66(10):2675\u201384.","journal-title":"Arthritis Rheumatol."},{"issue":"10","key":"835_CR61","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","volume":"75","author":"JR Curtis","year":"2016","unstructured":"Curtis JR, Xie F, Yun H, et al. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1843\u20137.","journal-title":"Ann Rheum Dis"},{"key":"835_CR62","doi-asserted-by":"crossref","unstructured":"Vieira MC, Zwillich SH, Jansen JP, et al. Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors: results from a network meta-analysis. Clin Ther. 2016;38(12):2628\u201341.e5.","DOI":"10.1016\/j.clinthera.2016.11.004"},{"key":"835_CR63","doi-asserted-by":"crossref","first-page":"8417249","DOI":"10.1155\/2017\/8417249","volume":"2017","author":"E Bergrath","year":"2017","unstructured":"Bergrath E, Gerber RA, Gruben D, et al. Tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients who have had an inadequate response to nonbiologic DMARDs: systematic literature review and network meta-analysis. Int J Rheumatol. 2017;2017:8417249.","journal-title":"Int J Rheumatol."},{"issue":"7","key":"835_CR64","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652\u201362.","journal-title":"N Engl J Med"},{"issue":"Suppl 10","key":"835_CR65","first-page":"2352","volume":"69","author":"M Weinblatt","year":"2017","unstructured":"Weinblatt M, Taylor PC, Burmester GR, et al. Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis [abstract no. 2352]. Arthritis. Rheumatol. 2017;69(Suppl 10):2352.","journal-title":"Rheumatol."},{"key":"835_CR66","unstructured":"Eli Lilly and Co Ltd. Olumiant (baricitinib): UK summary of product characteristics. 2017. https:\/\/www.medicines.org.uk\/emc\/medicine\/32997# . Accessed 31 Oct 2017."},{"issue":"3","key":"835_CR67","first-page":"523","volume":"55","author":"A Souto","year":"2016","unstructured":"Souto A, Maneiro JR, Gomez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford). 2016;55(3):523\u201334.","journal-title":"Rheumatology (Oxford)"},{"key":"835_CR68","unstructured":"Smith T, Harnett J, Gruben D, et al. Real-world experience with tofacitinib versus adalimumab and etanercept in biologic-naive patients with RA previously treated with methotrexate: data from a US administrative healthcare insurance claims database [abstract no. 2831]. Arthritis Rheumatol. 2017;69(Suppl 10)."},{"issue":"5","key":"835_CR69","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2217\/ijr.15.39","volume":"10","author":"MF Marengo","year":"2015","unstructured":"Marengo MF, Suarez-Almazor ME. Improving treatment adherence in patients with rheumatoid arthritis: what are the options? Int J Clin Rheumtol. 2015;10(5):345\u201356.","journal-title":"Int J Clin Rheumtol."},{"key":"835_CR70","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2147\/PPA.S117774","volume":"10","author":"R Alten","year":"2016","unstructured":"Alten R, Kruger K, Rellecke J, et al. Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach. Patient Prefer Adherence. 2016;10:2217\u201328.","journal-title":"Patient Prefer Adherence."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0835-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0835-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0835-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,6]],"date-time":"2019-10-06T03:17:15Z","timestamp":1570331835000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0835-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,14]]},"references-count":70,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["835"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0835-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,14]]}}}